About: Development of a Chimeric DNA-RNA Hammerhead Ribozyme Targeting SARS Virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of a Chimeric DNA-RNA Hammerhead Ribozyme Targeting SARS Virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Development of a Chimeric DNA-RNA Hammerhead Ribozyme Targeting SARS Virus
Creator	Taguchi, Fumihiro Fukuda, Noboru Fukushima, Akiko Iguchi, Akifumi Kuroda, Kazumichi Lai, Yimu Moriyama, Mitsuhiko Shimizu, Kazushi Ueno, Takahiro
source	Medline; PMC
abstract	OBJECTIVE: Severe acute respiratory syndrome (SARS) is a severe pulmonary infectious disease caused by a novel coronavirus. To develop an effective and specific medicine targeting the SARS-coronavirus (CoV), a chimeric DNA-RNA hammerhead ribozyme was designed and synthesized using a sequence homologous with the mouse hepatitis virus (MHV). METHOD: Chimeric DNA-RNA hammerhead ribozyme targeting MHV and SARS-CoV were designed and synthesized. To confirm its activity, in vitro cleavage reactions were performed with the synthesized ribozyme. Effects of the chimeric ribozyme were evaluated on multiplication of MHV. Effects of the chimeric ribozyme on expression of SARS-CoV were evaluated in cultured 3T3 cells. RESULT: The synthetic ribozyme cleaved the synthetic target MHV and SARS-CoV RNA into fragments of predicted length. The chimeric DNA-RNA hammerhead ribozyme targeting SARS-CoV significantly inhibited multiplication of MHV in DBT cells by about 60%. The chimeric DNA-RNA hammerhead ribozyme targeting SARS-CoV significantly inhibited the expression of SARS-CoV RNA in 3T3 cells transfected with the recombinant plasmid. The chimeric DNA-RNA ribozyme targeting SARS-CoV significantly inhibited MHV viral activity and expression of recombinant SARS RNA in vitro. CONCLUSION: These findings indicate that the synthetic chimeric DNA-RNA ribozyme could provide a feasible treatment for SARS.
has issue date	2009-05-07(xsd:dateTime)
bibo:doi	10.1159/000215946
bibo:pmid	19420961
has license	no-cc
sha1sum (hex)	18b897651abc24677f04d838cffd6b10bf0c4d88
schema:url	https://doi.org/10.1159/000215946
resource representing a document's title	Development of a Chimeric DNA-RNA Hammerhead Ribozyme Targeting SARS Virus
has PubMed Central identifier	PMC7179559
has PubMed identifier	19420961
schema:publication	Intervirology
resource representing a document's body	covid:18b897651abc24677f04d838cffd6b10bf0c4d88#body_text
is schema:about of	named entity 'ribozyme' named entity 'MHV' named entity 'MHV' named entity 'cleavage' named entity 'develop' named entity 'fragments' named entity 'Effects' named entity 'karger' covid:arg/18b897651abc24677f04d838cffd6b10bf0c4d88 named entity 'cells' named entity 'targeting' named entity 'synthesized' named entity 'evaluated' named entity 'virus' named entity 'specific' named entity 'effective' named entity 'caused' named entity 'chimeric' named entity 'ribozyme' named entity 'Chimeric' named entity 'SARS-CoV' named entity 'hammerhead ribozyme' named entity 'MHV' named entity 'ribozyme' named entity 'ribozyme' named entity 'RNA' named entity 'Severe acute respiratory syndrome' named entity 'MHV' named entity 'chimeric DNA' named entity 'MHV' named entity 'SARS' named entity '+41' named entity 'RNA' named entity 'ribozymes' named entity 'ribozyme' named entity 'RNA' named entity 'denatured' named entity 'SARS-CoV' named entity 'inhibit gene expression' named entity 'RNAi machinery' named entity 'Minimum Free Energy' named entity 'electrophoresis' named entity 'ribozyme' named entity 'SARS-CoV' named entity 'DTT' named entity 'ribozyme' named entity 'gene therapy' named entity 'ribozyme' named entity 'RNA' named entity 'RNA' named entity 'cationic' named entity 'RNA' named entity 'siRNA' named entity 'RNA' named entity 'ribozyme' named entity 'ribozyme' named entity 'hepatitis C virus' named entity 'chimeric DNA' named entity 'chimeric DNA' named entity 'coronaviruses' named entity '3T3' named entity 'dose-dependent manner' named entity 'RNA' named entity 'ribozyme' named entity 'RNA' named entity 'ribozyme' named entity 'antibodies' named entity 'nucleotides' named entity 'genome sequence' named entity 'tumor' named entity 'agarose gels' named entity 'ribozyme' named entity 'electrophoresis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software